KZR•benzinga•
Kezar Announces Topline Results From PRESIDIO Trial Of Zetomipzomib For The Treatment Of Dermatomyositis And Polymyositis
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 3, 2022 by benzinga